Study identifier:137-153
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
-
Diabetes Mellitus, Type 1
Phase 2
No
Pramlintide acetate
All
75
Interventional
18 Years - 70 Years
Allocation: Randomized
Endpoint Classification: Bio-availability
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jun 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This is a randomized, open-label, crossover study to examine the bioavailability of pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes mellitus using insulin.
Location
Location
New Orleans, LA, United States
Location
Orlando, FL, United States
Location
Minneapolis, MN, United States
Location
Austin, TX, United States
Arms | Assigned Interventions |
---|---|
Active Comparator: Pramlintide acetate (AC137) injection | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.